Jack Higgins
Chief Tech/Sci/R&D Officer at IMMUNOME, INC.
Net worth: - $ as of 2024-04-29
Profile
Jack Higgins is currently the Chief Scientific Officer at Immunome, Inc. He previously worked as the Chief Development Sciences Officer at Molecular Templates, Inc. from 2010 to 2021 and again from 2019 to 2021.
He also served as the Chief Scientific Officer at MorphImmune, Inc. from 2022 to 2023.
Dr. Higgins obtained his undergraduate degree from Texas A&M University and his graduate and doctorate degrees from The University of Arkansas.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
IMMUNOME, INC.
-.--% | 2024-03-31 | 0 ( -.--% ) | - $ | 2024-04-29 |
Jack Higgins active positions
Companies | Position | Start |
---|---|---|
IMMUNOME, INC. | Chief Tech/Sci/R&D Officer | 2023-10-01 |
Former positions of Jack Higgins
Companies | Position | End |
---|---|---|
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Chief Tech/Sci/R&D Officer | 2023-09-30 |
Molecular Templates, Inc. /Old/
Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | Chief Operating Officer | 2019-05-31 |
MOLECULAR TEMPLATES, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Jack Higgins
The University of Arkansas | Doctorate Degree |
Texas A&M University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
MOLECULAR TEMPLATES, INC. | Health Technology |
IMMUNOME, INC. | Health Technology |
Private companies | 2 |
---|---|
Molecular Templates, Inc. /Old/
Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | Health Technology |
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Health Technology |
- Stock Market
- Insiders
- Jack Higgins